Literature DB >> 21224046

Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens.

Gustavo E Ayala1, Bahar Muezzinoglu, Kai H Hammerich, Anna Frolov, Hao Liu, Peter T Scardino, Rile Li, Mohammad Sayeeduddin, Michael M Ittmann, Dov Kadmon, Brian J Miles, Thomas M Wheeler, David R Rowley.   

Abstract

We previously reported that reactive stroma grading in prostate cancer (PCa) is predictive of biochemical recurrence in prostatectomies and biopsies. In this study, we tested whether quantifying the percentage of reactive stromal grade 3 (RSG 3; stromogenic carcinoma pattern) in the entire tumor is predictive of PCa-specific death. Whole-mount prostatectomies operated by a single surgeon obtained between 1983 and 1998 were reviewed. Reactive stroma was evaluated as described previously, and areas of RSG 3 in the entire tumor were registered as percentages of total tumor. Statistical analysis was performed using Spearman, Kaplan-Meier, and Cox analyses. In all, 872 cases were evaluable. Quantification of RSG 3 percentage was an independent predictor of biochemical recurrence, analyzed as a continuous or grouped variable. Patients with higher RSG 3 percentages (larger tumor areas with RSG 3) had a significantly decreased biochemical recurrence-free survival than those with a lower RSG 3 percentage, even within the Gleason score 7 subset of patients. A nomogram introduced this new variable to the model. Furthermore, quantification of RSG 3 percentage was significantly predictive of PCa-specific death. Quantification of the RSG 3 (stromogenic carcinoma) area in PCa provides additional novel information on prognosis. These data substantiate the concept that the tumor microenvironment holds significant predictive information, as well as biological significance. Copyright Â
© 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21224046      PMCID: PMC3069909          DOI: 10.1016/j.ajpath.2010.09.042

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

1.  Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model.

Authors:  Jennifer A Tuxhorn; Stephanie J McAlhany; Feng Yang; Truong D Dang; David R Rowley
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

Review 2.  Histologic grading of prostate cancer: a perspective.

Authors:  D F Gleason
Journal:  Hum Pathol       Date:  1992-03       Impact factor: 3.466

3.  Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens.

Authors:  N Maru; M Ohori; M W Kattan; P T Scardino; T M Wheeler
Journal:  Hum Pathol       Date:  2001-08       Impact factor: 3.466

4.  Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.

Authors:  Tobias Zellweger; Christoph Ninck; Martina Mirlacher; Matthias Annefeld; Andrew G Glass; Thomas C Gasser; Michael J Mihatsch; Edward P Gelmann; Lukas Bubendorf
Journal:  Prostate       Date:  2003-04-01       Impact factor: 4.104

5.  Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy.

Authors:  Nobuyuki Yanagisawa; Rile Li; David Rowley; Hao Liu; Dov Kadmon; Brian J Miles; Thomas M Wheeler; Gustavo E Ayala
Journal:  Hum Pathol       Date:  2008-02       Impact factor: 3.466

6.  Growth and survival mechanisms associated with perineural invasion in prostate cancer.

Authors:  Gustavo E Ayala; Hong Dai; Michael Ittmann; Rile Li; Michael Powell; Anna Frolov; Thomas M Wheeler; Timothy C Thompson; David Rowley
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

7.  Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

Authors:  Martine P Roudier; Lawrence D True; Celestia S Higano; Hubert Vesselle; William Ellis; Paul Lange; Robert L Vessella
Journal:  Hum Pathol       Date:  2003-07       Impact factor: 3.466

8.  Global gene expression analysis of reactive stroma in prostate cancer.

Authors:  Olga Dakhova; Mustafa Ozen; Chad J Creighton; Rile Li; Gustavo Ayala; David Rowley; Michael Ittmann
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

Review 9.  Epidemiology of prostate cancer.

Authors:  E David Crawford
Journal:  Urology       Date:  2003-12-22       Impact factor: 2.649

10.  The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.

Authors:  M Ohori; T M Wheeler; J K Dunn; T A Stamey; P T Scardino
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

View more
  27 in total

Review 1.  Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo.

Authors:  Takeshi Sasaki; Omar E Franco; Simon W Hayward
Journal:  Differentiation       Date:  2017-07-20       Impact factor: 3.880

Review 2.  Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Joshua M Lang; Robert B Den; Isla P Garraway; Tamara L Lotan; Ashley E Ross; Tanya Stoyanova; Steve Y Cho; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2015-10-19       Impact factor: 4.104

Review 3.  Hedgehog signaling in prostate epithelial-mesenchymal growth regulation.

Authors:  Yu-Ching Peng; Alexandra L Joyner
Journal:  Dev Biol       Date:  2015-01-29       Impact factor: 3.582

Review 4.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

5.  RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation.

Authors:  Woosook Kim; David A Barron; Rebeca San Martin; Keith S Chan; Linda L Tran; Feng Yang; Steven J Ressler; David R Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

6.  Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer.

Authors:  Ya-Qiang Huang; Zhao-Dong Han; Yu-Xiang Liang; Zhuo-Yuan Lin; Xiao-Hui Ling; Xin Fu; Chao Cai; Xue-Cheng Bi; Qi-Shan Dai; Jia-Hong Chen; Hui-Chan He; Yan-Ru Chen; Fu-Neng Jiang; Wei-de Zhong
Journal:  Med Oncol       Date:  2013-12-14       Impact factor: 3.064

7.  Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo.

Authors:  Olga Dakhova; David Rowley; Michael Ittmann
Journal:  Clin Cancer Res       Date:  2013-10-22       Impact factor: 12.531

8.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Authors:  Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

9.  FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma.

Authors:  Julienne L Carstens; Payam Shahi; Susan Van Tsang; Billie Smith; Chad J Creighton; Yiqun Zhang; Amber Seamans; Mamatha Seethammagari; Indira Vedula; Jonathan M Levitt; Michael M Ittmann; David R Rowley; David M Spencer
Journal:  Cancer Res       Date:  2013-12-04       Impact factor: 12.701

Review 10.  The Stromal Niche for Epithelial Stem Cells: A Template for Regeneration and a Brake on Malignancy.

Authors:  Kelsey J Roberts; Aaron M Kershner; Philip A Beachy
Journal:  Cancer Cell       Date:  2017-10-09       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.